Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06124261 · ClinicalTrials.gov registry record
Androgens and NAFLD Longitudinal Cohort Study
A clinical trial of NAFLD and NASH, sponsored by University of California, San Francisco.
- Recruiting
- Registry status
- 150
- Enrollment target
- 2
- Study locations
NCT06124261: Recruiting study of NAFLD and NASH, sponsored by University of California, San Francisco.
NCT06124261 is a study of NAFLD and NASH that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 150 participants, roughly in line with the 159-participant average among 26 other NAFLD trials with a reported enrollment target. The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06124261, a study of NAFLD and NASH, is actively recruiting participants, sponsored by University of California, San Francisco.
- RECRUITING
- Registry status
- 150 participants
- Enrollment target
- 2
- Study locations
Study Summary
The researchers want to learn how androgens, a type of sex hormone, might affect nonalcoholic fatty liver (NAFLD) in young women over time. NAFLD happens when fat builds up in the liver which can cause damage to the liver such as inflammation or scarring. Young women with a condition called polycystic ovary syndrome (PCOS) have a high risk for NAFLD, and they often have high androgen levels too. So the researchers are recruiting young women with PCOS as well as those without PCOS, and will compare changes in NAFLD over time between young women with and without PCOS. This study is funded by the National Institutes of Health
Primary Outcome
Mean change in liver stiffness (kPA) on magnetic resonance elastography (MRE)
Study Locations (2)
California
- University of California San Francisco - San Francisco
North Carolina
- Duke University - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2024-01-22 |
| Est. Completion | 2028-12 |
What NCT06124261 shows while recruiting
NCT06124261 is an observational study that tracks outcomes without assigning an intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 159-participant average among 26 other NAFLD trials with a reported enrollment target.
The record links to 3 conditions, with NAFLD appearing as the primary indexed condition, and to 0 interventions.
NCT06124261 reports a single indexed study location in California, North Carolina.
Frequently Asked Questions
What is clinical trial NCT06124261 about?
NCT06124261 is a clinical study titled "Androgens and NAFLD Longitudinal Cohort Study". The researchers want to learn how androgens, a type of sex hormone, might affect nonalcoholic fatty liver (NAFLD) in young women over time. NAFLD happens when fat builds up in the liver which can cause damage to the liver such as inflammation or scarring. Young women with a condition called polycys...
What is the current status of trial NCT06124261?
This trial is currently recruiting. The enrollment target is 150 participants. The study started on 2024-01-22. Estimated completion is 2028-12.
What conditions does trial NCT06124261 study?
This clinical trial studies the following conditions: NAFLD, NASH, PCOS.
Who is sponsoring clinical trial NCT06124261?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06124261 being conducted?
This trial has 2 study locations across California, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for NAFLD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06124261's enrollment target sits among peer trials
150 7th of 26 higher than 20 of 26 other NAFLD trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NAFLD trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pathogenesis of Pediatric Nonalcoholic Fatty Liver Disease (NAFLD)
RECRUITING
-
Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant
RECRUITING · Phase 2
-
Reversal of Lipid-Induced Insulin Resistance
RECRUITING · NA
-
Digoxin In NASH (CODIN)
RECRUITING · Phase 2
-
Effect of Amino Acids on Hepatic Fat Content in Adolescents (AMINOS Study)
RECRUITING · Phase 3
-
Bicalutamide Therapy in Young Women With NAFLD and PCOS
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI